MCID: MLT074
MIFTS: 54

Multiple Endocrine Neoplasia

Categories: Cancer diseases, Genetic diseases, Rare diseases, Gastrointestinal diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Multiple Endocrine Neoplasia

MalaCards integrated aliases for Multiple Endocrine Neoplasia:

Name: Multiple Endocrine Neoplasia 25 29 52 69
Multiple Endocrine Neoplasia Type 1 69
Adenomatosis, Familial Endocrine 25
Multiple Endocrine Adenomatosis 25
Familial Endocrine Adenomatosis 25
Endocrine Neoplasia, Multiple 25
Multiple Endocrine Neoplasms 25
Mea 25
Men 25

Classifications:



Summaries for Multiple Endocrine Neoplasia

Genetics Home Reference : 25 Multiple endocrine neoplasia is a group of disorders that affect the body's network of hormone-producing glands called the endocrine system. Hormones are chemical messengers that travel through the bloodstream and regulate the function of cells and tissues throughout the body. Multiple endocrine neoplasia typically involves tumors (neoplasia) in at least two endocrine glands; tumors can also develop in other organs and tissues. These growths can be noncancerous (benign) or cancerous (malignant). If the tumors become cancerous, the condition can be life-threatening.

MalaCards based summary : Multiple Endocrine Neoplasia, also known as multiple endocrine neoplasia type 1, is related to multiple endocrine neoplasia iib and medullary thyroid carcinoma, familial, and has symptoms including diarrhea An important gene associated with Multiple Endocrine Neoplasia is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Neuroscience and Signaling events regulated by Ret tyrosine kinase. The drugs Histamine and Morphine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, breast and testes, and related phenotypes are Decreased viability and cardiovascular system

Wikipedia : 72 The term multiple endocrine neoplasia (MEN) encompasses several distinct syndromes featuring tumors of... more...

Related Diseases for Multiple Endocrine Neoplasia

Diseases in the Multiple Endocrine Neoplasia family:

Multiple Endocrine Neoplasia Iia Multiple Endocrine Neoplasia Iib
Multiple Endocrine Neoplasia 1 Multiple Endocrine Neoplasia, Type Iv

Diseases related to Multiple Endocrine Neoplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 205)
id Related Disease Score Top Affiliating Genes
1 multiple endocrine neoplasia iib 31.8 CALCA GDNF MEN1 NF1 RET SDHB
2 medullary thyroid carcinoma, familial 31.4 CALCA CHGA GDNF MEN1 RET
3 hyperparathyroidism-jaw tumor syndrome 30.5 MEN1 RET
4 parathyroid carcinoma 30.5 CALCA MEN1
5 cavernous hemangioma 29.3 CHGA RET
6 gastrointestinal stromal tumor 28.5 NF1 SDHB SDHC
7 paraganglioma 27.8 CHGA NF1 RET SDHB SDHC VHL
8 pheochromocytoma 27.4 CALCA CHGA GDNF MEN1 NF1 PNMT
9 multiple endocrine neoplasia iia 12.7
10 multiple endocrine neoplasia 1 12.7
11 multiple endocrine neoplasia, type iv 12.5
12 zollinger-ellison syndrome 11.4
13 insulinoma 11.3
14 pancreatic neuroendocrine tumor 11.3
15 acromegaly 11.3
16 vipoma 11.3
17 gigantism 11.3
18 adrenal carcinoma 11.3
19 pancreatic cholera 11.3
20 pituitary adenoma, prolactin-secreting 11.1
21 pituitary adenoma, acth-secreting 11.0
22 hereditary paraganglioma-pheochromocytoma syndromes 11.0
23 pemphigus foliaceus 10.7 CALCA MEN1
24 pandas 10.7 CALCA MEN1
25 thyroiditis 10.7
26 iris mixed cell melanoma 10.6 CALCA MEN1
27 megalocytic interstitial nephritis 10.6 GDNF RET
28 early-onset parkinson disease 10.6 MEN1 RET
29 congenital granular cell tumor 10.6 CALCA CHGA
30 hypogonadotropic hypogonadism without anosmia, x-linked 10.6 GDNF RET
31 cowden syndrome 3 10.6 CHGA MEN1
32 parietal lobe neoplasm 10.6 CALCA CHGA
33 hyperparathyroidism 10.6
34 brain stem ependymoma 10.6 CHGA MEN1
35 diffuse lipomatosis 10.5 CHGA VHL
36 spinal muscular atrophy 10.5 CALCA CHGA
37 gastric gastrinoma 10.5 CALCA CHGA
38 primary progressive multiple sclerosis 10.5 CHGA MEN1
39 pancreatitis 10.5
40 tricuspid valve insufficiency 10.5 CALCA CHGA
41 mononeuritis of upper limb and mononeuritis multiplex 10.5 MEN1 PRKAR1A
42 lung giant cell carcinoma 10.5 CHGA MEN1
43 opioid abuse 10.4 CALCA MEN1 RET
44 volkmann contracture 10.4 CHGA MEN1
45 tricuspid valve prolapse 10.4 CALCA CHGA
46 neuroendocrine tumor 10.4
47 nodular prostate 10.4 CALCA RET
48 bladder diffuse clear cell adenocarcinoma 10.4 CALCA CDKN1B RET
49 waardenburg syndrome, type 4b 10.4 CALCA PRKAR1A
50 osseous heteroplasia, progressive 10.4 MEN1 PRKAR1A

Graphical network of the top 20 diseases related to Multiple Endocrine Neoplasia:



Diseases related to Multiple Endocrine Neoplasia

Symptoms & Phenotypes for Multiple Endocrine Neoplasia

UMLS symptoms related to Multiple Endocrine Neoplasia:


diarrhea

GenomeRNAi Phenotypes related to Multiple Endocrine Neoplasia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.81 RET VHL CDKN1B NF1 PRKAR1A
2 Decreased viability GR00221-A-2 9.81 PRKAR1A RET VHL NF1
3 Decreased viability GR00221-A-3 9.81 PRKAR1A
4 Decreased viability GR00221-A-4 9.81 PRKAR1A RET NF1
5 Decreased viability GR00231-A 9.81 RET
6 Decreased viability GR00301-A 9.81 RET VHL
7 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 VHL NF1

MGI Mouse Phenotypes related to Multiple Endocrine Neoplasia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.16 GDNF RET MEN1 SDHB CDKN1B NF1
2 endocrine/exocrine gland MP:0005379 10.02 GDNF RET MEN1 SDHB CDKN1B NF1
3 mortality/aging MP:0010768 10.02 PRKAR1A GDNF RET MEN1 CDKN1B NF1
4 digestive/alimentary MP:0005381 9.95 PRKAR1A GDNF RET MEN1 CDKN1B NF1
5 craniofacial MP:0005382 9.83 PRKAR1A MEN1 NF1 CDKN1B VHL
6 muscle MP:0005369 9.8 PRKAR1A GDNF RET MEN1 CDKN1B NF1
7 neoplasm MP:0002006 9.7 RET MEN1 CDKN1B NF1 PRKAR1A SDHB
8 renal/urinary system MP:0005367 9.43 GDNF RET CDKN1B NF1 CHGA VHL
9 reproductive system MP:0005389 9.17 CHGA PRKAR1A GDNF RET MEN1 CDKN1B

Drugs & Therapeutics for Multiple Endocrine Neoplasia

Drugs for Multiple Endocrine Neoplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 311)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
2
Morphine Approved, Investigational Phase 4 57-27-2 5288826
3
Vancomycin Approved Phase 4 1404-90-6 441141 14969
4
Dexlansoprazole Approved Phase 4 138530-94-6, 103577-45-3 9578005
5
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
6
Somatostatin Approved Phase 4,Phase 3,Phase 2 38916-34-6, 51110-01-1 53481605
7
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
9
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
10
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
11
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
12
Liraglutide Approved Phase 4 204656-20-2 44147092
13
Metformin Approved Phase 4 657-24-9 14219 4091
14
Zinc Approved Phase 4 7440-66-6 32051 23994
15
Sunitinib Approved, Investigational Phase 4,Phase 2 341031-54-7, 557795-19-4 5329102
16
Iodine Investigational Phase 4,Phase 3,Phase 2,Phase 1 7553-56-2 807
17
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents, Local Phase 4,Phase 3,Phase 1
20 cadexomer iodine Phase 4,Phase 3,Phase 2,Phase 1
21 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
22 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
23 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
24 Hormones Phase 4,Phase 3,Phase 2,Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
26 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
27 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
29
Histamine Phosphate Phase 4 51-74-1 65513
30 Antacids Phase 4
31 Anti-Ulcer Agents Phase 4
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
33
Proton pump inhibitors Phase 4
34 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
35 Aromatase Inhibitors Phase 4,Phase 2,Phase 1
36 Bone Density Conservation Agents Phase 4,Phase 2,Phase 1
37 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1
38 Estrogens Phase 4,Phase 3,Phase 2,Phase 1
39 Steroid Synthesis Inhibitors Phase 4,Phase 2,Phase 1
40 HIV Protease Inhibitors Phase 4,Phase 1,Phase 2
41
protease inhibitors Phase 4,Phase 1,Phase 2
42 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
43 Antifungal Agents Phase 4,Phase 2
44 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Estrogen Receptor Modulators Phase 4,Phase 2,Phase 1
46 Selective Estrogen Receptor Modulators Phase 4,Phase 2,Phase 1
47 Dipeptidyl-Peptidase IV Inhibitors Phase 4
48 Hypoglycemic Agents Phase 4
49 Incretins Phase 4
50 insulin Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 315)

id Name Status NCT ID Phase Drugs
1 rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
2 Vancomycin Associated Red Man Syndrome (RMS) Completed NCT00824122 Phase 4
3 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
4 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
5 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
6 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Recruiting NCT02605213 Phase 4 Vancomycin;Placebo
7 Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Recruiting NCT02089854 Phase 4 Toremifene; Anastrozole
8 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
9 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
10 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
11 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
12 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
13 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
14 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
15 Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours Completed NCT00353496 Phase 3 lanreotide (Autogel formulation);Placebo
16 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous formulation
17 Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer Completed NCT00024427 Phase 3 fluorouracil;gemcitabine hydrochloride;triacetyluridine
18 Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer Completed NCT01819285 Phase 3
19 Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Completed NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
20 Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
21 Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer Completed NCT00052468 Phase 3 TCG;TC
22 Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
23 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
24 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
25 Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen Completed NCT00417209 Phase 3 Larotaxel (XRP9881);5-Fluorouracil;Capecitabine
26 Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3 ON 01910.Na;Gemcitabine;Gemcitabine
27 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Completed NCT00976911 Phase 3 bevacizumab [Avastin];liposomal doxorubicin;paclitaxel;topotecan
28 Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma Completed NCT00044031 Phase 3
29 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
30 The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer Completed NCT00794053 Phase 3
31 A Study to Compare Treatment After Surgery of Abemaciclib (LY2835219) Combined With Standard Endocrine Therapy Versus Endocrine Therapy Alone in Participants With Breast Cancer Recruiting NCT03155997 Phase 3 Abemaciclib;Standard Adjuvant Endocrine Therapy
32 Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer Recruiting NCT03078751 Phase 3 Ribociclib;Placebo;Adjuvant endocrine therapy
33 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
34 Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors Recruiting NCT02589821 Phase 3 Sulfatinib
35 Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer Recruiting NCT02012634 Phase 3
36 Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments. Recruiting NCT02282020 Phase 3 OLAPARIB;Single agent chemotherapy
37 Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection Recruiting NCT02506842 Phase 3 nab-paclitaxel;gemcitabine;oxaliplatin;folinic acid;fluorouracil
38 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Recruiting NCT02395016 Phase 3 nimotuzumab;Gemcitabine
39 Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy Recruiting NCT02457156 Phase 3 Octreotide
40 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
41 Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer Recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
42 European Celecoxib Trial in Primary Breast Cancer Active, not recruiting NCT02429427 Phase 3 Celecoxib
43 An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
44 Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy Active, not recruiting NCT02404363 Phase 3 Clopidogrel;Placebo
45 Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Active, not recruiting NCT02422615 Phase 3 Ribociclib;fulvestrant;Ribociclib placebo
46 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699
47 Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment Not yet recruiting NCT02705651 Phase 3 Somatostatin-Analog
48 Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer Not yet recruiting NCT03081234 Phase 3 Ribociclib;Placebo;Adjuvant endocrine therapy
49 Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer Terminated NCT01956812 Phase 3 IMMU-107;placebo;Gemcitabine
50 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo

Search NIH Clinical Center for Multiple Endocrine Neoplasia

Genetic Tests for Multiple Endocrine Neoplasia

Genetic tests related to Multiple Endocrine Neoplasia:

id Genetic test Affiliating Genes
1 Multiple Endocrine Neoplasia 29

Anatomical Context for Multiple Endocrine Neoplasia

MalaCards organs/tissues related to Multiple Endocrine Neoplasia:

39
Thyroid, Breast, Testes, Pituitary, Bone, Lung, Prostate

Publications for Multiple Endocrine Neoplasia

Articles related to Multiple Endocrine Neoplasia:

(show top 50) (show all 1157)
id Title Authors Year
1
Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1. ( 28919049 )
2017
2
Prognostic value of WHO grade in pancreatic neuro-endocrine tumors in Multiple Endocrine Neoplasia type 1: Results from the DutchMEN1 Study Group. ( 28811081 )
2017
3
Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades. ( 28605116 )
2017
4
Novel Somatic RET Mutation Questioning the Causality of the RET I852M Germline Sequence Variant in Multiple Endocrine Neoplasia 2A. ( 28578594 )
2017
5
Aggressive adrenal carcinoma in a young patient with Multiple Endocrine Neoplasia 1 syndrome. ( 28625514 )
2017
6
Laparoscopic total pancreatectomy for multiple endocrine neoplasia type 1 syndrome-associated multifocal, non-functioning pancreatic neuroendocrine tumor: A case report. ( 28589571 )
2017
7
Lung adenocarcinoma and adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1. ( 28070481 )
2017
8
Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE for Metastatic Neuroendocrine Tumor Occurring in Association with Multiple Endocrine Neoplasia Type 1 and Cushing's Syndrome. ( 28553179 )
2017
9
Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. ( 28674121 )
2017
10
Clinical Features of a Family with Multiple Endocrine Neoplasia Type 2A Caused by the D631Y RET Mutation. ( 28747092 )
2017
11
Genetic diagnosis of a Chinese multiple endocrine neoplasia type 2A family through whole genome sequencing. ( 28569245 )
2017
12
Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study. ( 27975336 )
2017
13
Operative intervention for primary hyperparathyroidism offers greater bone recovery in patients with sporadic disease than in those with multiple endocrine neoplasia type 1-related hyperparathyroidism. ( 27842919 )
2017
14
Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. ( 27770475 )
2017
15
Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1: Reply. ( 27847968 )
2017
16
Incidental Detection of Synchronous Medullary Thyroid Carcinoma with Bilateral Adrenal Pheochromocytoma on Iodine-123 Metaiodobenzylguanidine Scintigraphy, Leading to Diagnosis of Multiple Endocrine Neoplasia 2A. ( 28553188 )
2017
17
Multiple endocrine neoplasia 2B: Differential increase in enteric nerve subgroups in muscle and mucosa. ( 28868184 )
2017
18
Disease and treatment factors associated with lower quality of life scores in adults with multiple endocrine neoplasia type I. ( 28919050 )
2017
19
Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with "highest risk" RET mutation. ( 28925363 )
2017
20
[Clinical features and mutations of RET proto-oncogene in a pedigree affected with type 2A multiple endocrine neoplasia]. ( 28186607 )
2017
21
Evidence for the founder effect of RET533 as the common Greek and Brazilian ancestor spreading multiple endocrine neoplasia 2A. ( 28137737 )
2017
22
A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11. ( 28943896 )
2017
23
Germline and somatic genetic changes in multicentric tumors obtained from a patient with multiple endocrine neoplasia type 1. ( 28503312 )
2017
24
Financial burden is associated with worse health-related quality of life in adults with multiple endocrine neoplasia type 1. ( 28923697 )
2017
25
Advances in risk-oriented surgery for multiple endocrine neoplasia type 2. ( 28883084 )
2017
26
Different RET gene mutation-induced multiple endocrine neoplasia type 2A in 3 Chinese families. ( 28099363 )
2017
27
Clinical Features and Prognosis of Thymic Neuroendocrine Tumors Associated with Multiple Endocrine Neoplasia Type 1: A Single Center Study, Systematic Review, and Meta-analysis. ( 28940393 )
2017
28
Challenging Differential Diagnosis of Hypergastremia and Hyperglucagonemia with Chronic Renal Failure: Report of a Case with Multiple Endocrine Neoplasia Type 1. ( 28566601 )
2017
29
Composite paraganglioma-ganglioneuroma concomitant with adrenal metastasis of medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 2B: A case report. ( 27704704 )
2017
30
Distribution of RET Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994-2014: A Nationwide Study. ( 27809725 )
2017
31
Multiple endocrine neoplasia type 1 (MEN1): An update of 208 new germline variants reported in the last nine years. ( 26767918 )
2016
32
Efficacy and Long-Term Safety of Everolimus in Pancreatic Neuroendocrine Tumor Associated with Multiple Endocrine Neoplasia Type I: Case Report. ( 27710978 )
2016
33
Novel multiple endocrine neoplasia type 1 variations in patients with sporadic primary hyperparathyroidism. ( 27366707 )
2016
34
A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma. ( 27400880 )
2016
35
Pituitary Prolactinoma Imaged by 99mTc-Sestamibi SPECT/CT in a Multiple Endocrine Neoplasia Type 1 Patient. ( 26828146 )
2016
36
A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A. ( 27838608 )
2016
37
Cutaneous lichen amyloidosis in multiple endocrine neoplasia. ( 26813904 )
2016
38
Corneal xanthogranuloma in association with multiple endocrine neoplasia 1: A clinicopathologic case report and review of the literature. ( 26949359 )
2016
39
Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. ( 26834963 )
2016
40
Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression. ( 26990064 )
2016
41
Multiple endocrine neoplasia type 1 associated with a new germline Men1 mutation in a family with atypical tumor phenotype. ( 26732163 )
2016
42
Perioperative Severe Hypotension in a Patient with Multiple Endocrine Neoplasia Type IIb and Bilateral Adrenalectomies: Time to Review the Evidence for Stress Dose Steroids. ( 27900224 )
2016
43
Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. ( 27256431 )
2016
44
Clinical significance of RET mutation screening in a pedigree of multiple endocrine neoplasia type 2A. ( 27277749 )
2016
45
Multiple Endocrine Neoplasia Syndromes: A Comprehensive Imaging Review. ( 27153782 )
2016
46
Parathyroid morphology and menin stainingA in multiple endocrine neoplasia type 1 (MEN 1). ( 27773149 )
2016
47
[Hyperparathyroidism in multiple endocrine neoplasia type 2A syndrome. Surgical and genetic implications]. ( 26589732 )
2016
48
Clinical and Genetic Analysis of Multiple Endocrine Neoplasia Type 1-Related Primary Hyperparathyroidism in Chinese. ( 27846313 )
2016
49
Pituitary adenoma associated with pheochromocytoma/paraganglioma: A new form of multiple endocrine neoplasia. ( 27639663 )
2016
50
Multiple endocrine neoplasia type 2 kindred with novel tandem RET mutations: Case report with an applied in silico mutational tolerance analysis. ( 26876062 )
2016

Variations for Multiple Endocrine Neoplasia

ClinVar genetic disease variations for Multiple Endocrine Neoplasia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 RET NM_020630.4(RET): c.2410G> T (p.Val804Leu) single nucleotide variant Pathogenic rs79658334 GRCh37 Chromosome 10, 43614996: 43614996

Expression for Multiple Endocrine Neoplasia

Search GEO for disease gene expression data for Multiple Endocrine Neoplasia.

Pathways for Multiple Endocrine Neoplasia

Pathways related to Multiple Endocrine Neoplasia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.77 CALCA NF1 PRKAR1A RET
2 10.74 GDNF RET
3 10.48 CDKN1B NF1 RET

GO Terms for Multiple Endocrine Neoplasia

Cellular components related to Multiple Endocrine Neoplasia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.96 SDHB SDHC
2 respiratory chain complex II GO:0045273 8.62 SDHB SDHC

Biological processes related to Multiple Endocrine Neoplasia according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.73 CDKN1B MEN1 NF1 VHL
2 metanephros development GO:0001656 9.55 GDNF NF1
3 tricarboxylic acid cycle GO:0006099 9.54 SDHB SDHC
4 aerobic respiration GO:0009060 9.52 SDHB SDHC
5 neural crest cell migration GO:0001755 9.51 GDNF RET
6 peripheral nervous system development GO:0007422 9.49 GDNF NF1
7 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.48 CDKN1B MEN1
8 negative regulation of osteoclast differentiation GO:0045671 9.46 CALCA NF1
9 response to pain GO:0048265 9.4 CALCA RET
10 sympathetic nervous system development GO:0048485 9.37 GDNF NF1
11 positive regulation of adenylate cyclase activity GO:0045762 9.26 CALCA NF1
12 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 9.16 NF1 RET
13 positive regulation of cAMP metabolic process GO:0030816 9.02 CHGA
14 enteric nervous system development GO:0048484 8.96 GDNF RET
15 MAPK cascade GO:0000165 8.92 GDNF MEN1 NF1 RET

Sources for Multiple Endocrine Neoplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....